newsfilter
← Latest News
GlobeNewswire·

Kuehn Law Encourages Investors of Regenxbio, Inc. to Contact Law Firm

  • Kuehn Law, PLLC is investigating whether Regenxbio, Inc. officers & directors breached fiduciary duties.
  • The investigation centers on allegations of false or misleading information regarding RGX-111 efficacy & safety.
  • The firm claims positive assertions of future trial success were made based on Phase I/II biomarker & safety data.
  • Shareholders who purchased RGNX prior to February 9, 2022, are invited to contact attorney Sophia Anne Silayan.
  • Kuehn Law covers all case costs & charges no fees to investor clients.
  • Shareholders are urged to act immediately due to potential time limits on enforcing rights.
  • Attorney advertising disclaimer states prior results do not guarantee similar outcomes.